Acino has signed an exclusive licensing agreement with Bioprojet, to register, market, commercialise, and distribute an innovative medicine in Saudi Arabia, with potential expansion to other countries in the Middle East.
For licensing, manufacturing, and supply of select Acino products across the Kingdom
Acino and Alpha Pharma will further the goals of Saudi Arabia’s Health Sector Transformation Programme
This acquisition complements our growth ambitions for South Africa and fortifies our investment in the country.
The smart and flexible way Acino manages its different businesses, and how the company is growing into a key player in the pharmaceutical industry. These two things make me very proud.